Tricaprilin Liquid Formulation PK Study

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of new liquid formulations of tricaprilin, with the aim of finding a suitable formulation to advance in development. This is a three-part, part-randomised study that include single-dose, food effect, and titration tolerability in up to 80 healthy participants.

Conditions

• Alzheimer Disease

Interventions

DRUG

AC-1202

Tricaprilin formulated as AC-1202

DRUG

AC-OLE-01

Tricaprilin Formulation

DRUG

AC-OLE-02

Tricaprilin Formulation

DRUG

AC-OLE-03

Tricaprilin Formulation

DRUG

AC-OLE-04

Tricaprilin Formulation

DRUG

AC-OLE-05

Tricaprilin Formulation

DRUG

AC-OLE-06

Tricaprilin Formulation

DRUG

AC-OLE-07

Tricaprilin Formulation

DRUG

AC-OLE-08

Tricaprilin Formulation

DRUG

AC-OLE-09

Tricaprilin Formulation

DRUG

AC-OLE-010

Tricaprilin Formulation

DRUG

AC-OLE-P

Placebo to tricaprilin formulation

Sponsors & Collaborators

• Cerecin

  lead INDUSTRY

Principal Investigators

• Study Director · Cerecin

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-08-31

Primary Completion

2022-03-18

Completion

2022-07-19

Countries

• Australia

Study Locations